Advertisement
Screener

Celularity Inc. (CELU) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

2.8 / 5 stars · 68/120 Roast Me

Celularity Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

Celularity Inc. (CELU) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-04-30

  • Celularity Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
  • Celularity Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
  • Celularity Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 0.00%.
  • Celularity Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
  • Celularity Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
  • Celularity Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
  • Celularity Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2025-12-310.00%
10-K · filed 2026-04-30
2025-09-300.00%
10-Q · filed 2025-11-14
2025-06-300.00%
10-Q · filed 2025-08-29
2024-12-310.00%
10-K · filed 2026-04-30
2024-09-300.00%
10-Q · filed 2025-11-14
2024-06-300.00%
10-Q · filed 2025-08-29
2024-03-310.00%
10-Q · filed 2025-08-29
2023-12-310.00%
10-K · filed 2024-07-30
2023-09-300.00%
10-Q · filed 2024-12-06
2023-06-300.00%
10-Q · filed 2024-11-07
2023-03-310.00%
10-Q · filed 2023-05-22
2022-12-310.00%
10-K · filed 2023-03-31
2022-09-300.00%
10-Q · filed 2022-11-10
2022-06-300.00%
10-Q · filed 2022-08-09
2022-03-310.00%
10-Q · filed 2022-05-16
2021-12-310.00%
10-K · filed 2022-03-31
2021-09-300.00%
10-Q · filed 2021-11-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
CervoMed Inc. (CRVO)United States$0.038B-1.39
Actinium Pharmaceuticals, Inc. (ATNM)United States$0.038B2.73
FILANA THERAPEUTICS, INC. (FLNA)United States$0.038B-1.05
PMGC Holdings Inc. (ELAB)United States$0.037B
Edesa Biotech, Inc. (EDSA)Canada$0.039B
BriaCell Therapeutics Corp. (BCTX)$0.037B
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30
Incannex Healthcare Inc. (IXHL)$0.040B-22.32